Migraine

• Atogepant (brand name: Aquipta) was recently recommended by the National Institute for Health and Care Excellence (Nice) to prevent episodic and chronic migraine attacks.
• The drug would be recommended to people who have at least four migraine days a month or where at least three previous preventative treatments have failed.
• Migraine is a complex neurological condition that affects about 10 million people in the UK.
• It’s characterised by recurrent, severe headaches that can be made worse by physical activity and are often debilitating.
• However, it’s only suited to patients who suffer from episodic migraines – whereas atogepant can be used by people who have both chronic and episodic migraines.

Consistently effective

Three clinical trials have shown atogepant to be safe and effective for people with episodic or chronic migraines.

• The Advance trial evaluated how safe and effective different doses of atogepant were compared with a placebo in preventing episodic migraine.
• The 60mg once-daily tablet was found to be well tolerated and effective, leading to nearly seven fewer migraine days per month.
• A third trial, the 302-LTS trial, followed participants who suffered from episodic migraine for over a year, finding that atogepant was consistently effective for reducing migraine attacks.
• Atogenpant was consistently shown to be safe across all studies, including the one that lasted for a year.

Anna Andreou receives funding from the Medical Research Foundation and Brain Research UK. She also received research funding from eNeura, AbbVie and Pfizer. She is affiliated with the International Headache Society, being elected as a Trustee of the Board. She is Chair of the Headache special interest group of the British Pain Society.

• We are now well-positioned to plan for the initiation of our pivotal Phase 3 program,” commented Marc Forth, AEON’s President and Chief Executive Officer.
• “Recently, we announced plans to conduct an interim analysis of our ongoing Phase 2 study of ABP-450 as a preventive treatment for chronic migraine, which completed enrollment in December 2023.
• On track to announce topline results from the Phase 2 study of ABP-450 as a preventive treatment for chronic migraine in the third quarter of 2024.
• Episodic Migraine Program Next Steps – The Company is continuing to plan for the initiation of its proposed pivotal Phase 3 program for ABP-450.

• These data will be presented during an oral session at the 76th Annual Meeting of the American Academy of Neurology (AAN) taking place in Denver, Colo., and virtually from April 13-18, 2024.
• “Our real-world data helps us better understand how individuals are uniquely impacted by migraine beyond monthly headache days.
• We’re excited to continually partner with the migraine community to raise the bar on preventive treatment expectations.”
  VYEPTI is indicated for the preventive treatment of migraine in adults.
• The safety and efficacy of VYEPTI has not been evaluated for use in any psychiatric conditions.

• Moreover, caffeine powder offers consumers the flexibility to customize their caffeine intake according to their preferences and needs.
• In addition, the globalization of the caffeine powder market has led to increased accessibility and availability of products across regions and channels.
• Furthermore, Europe is home to several prominent pharmaceutical and food industries that utilize caffeine powder in various formulations, further bolstering market growth.
• With its robust market infrastructure, consumer demand, and regulatory framework, Europe is expected to maintain its leadership position in the global caffeine powder market.